Ignite Creation Date:
2025-12-26 @ 12:18 PM
Ignite Modification Date:
2026-01-14 @ 1:22 AM
Study NCT ID:
NCT03441100
Status:
COMPLETED
Last Update Posted:
2025-02-04
First Post:
2018-02-09
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
TCR-engineered T Cells in Solid Tumors: IMA202-101
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D012008', 'term': 'Recurrence'}], 'ancestors': [{'id': 'D020969', 'term': 'Disease Attributes'}, {'id': 'D010335', 'term': 'Pathologic Processes'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE1'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NA', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 16}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2019-05-02', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-02', 'completionDateStruct': {'date': '2023-03-17', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-02-03', 'studyFirstSubmitDate': '2018-02-09', 'studyFirstSubmitQcDate': '2018-02-20', 'lastUpdatePostDateStruct': {'date': '2025-02-04', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2018-02-22', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2022-06-17', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Incidence of adverse events (AE)', 'timeFrame': 'up to 3 years post treatment'}], 'secondaryOutcomes': [{'measure': 'Persistence of T-cells', 'timeFrame': 'up to 3 years post treatment'}, {'measure': 'Tumor response per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 and immune-related RECIST (irRECIST)', 'timeFrame': 'up to 12 months'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': True, 'isUnapprovedDevice': True, 'isFdaRegulatedDevice': True}, 'conditionsModule': {'keywords': ['T-Cell therapy', 'Immunotherapy', 'Adoptive cellular therapy', 'T-Cell Receptor', 'Cell Therapy', 'Cytotherapy', 'IMA202'], 'conditions': ['Solid Tumor, Adult', 'Refractory Cancer', 'Recurrent Cancer', 'Cancer']}, 'descriptionModule': {'briefSummary': 'The study purpose is to establish the safety and tolerability of IMA202 product in patients with solid tumors that express melanoma-associated antigen 1 (MAGEA1).', 'detailedDescription': "SCREENING: Patient eligibility will be determined by HLA (human leukocyte antigen) screening and a biopsy for biomarker screening. If the patient is eligible, white blood cells will be taken during leukapheresis for the manufacture of the IMA202 product.\n\nMANUFACTURING: IMA202 product will be made from the patient's white blood cells.\n\nTREATMENT: Lymphodepletion with cyclophosphamide and fludarabine will occur in the days before the IMA202 product infusion to improve the duration of time that IMA202 product stays in the body. The patient will be admitted to the hospital during the treatment.\n\nAfter the IMA202 product infusion, a low dose of IL-2 will be given twice daily for a period of time.\n\nPatients will be closely monitored for safety and for a total of 3 years post IMA202 infusion."}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n* Pathologically confirmed advanced and/or metastatic solid tumor\n* Patients may enter screening procedure before, during, or after the last available indicated standard of care treatment. There is no limitation for prior anti cancer treatments.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-1\n* HLA phenotype positive for the study\n* Measurable disease and accessible to biopsy\n* Adequate pulmonary function per protocol\n* Acceptable organ and bone marrow function per protocol\n* Acceptable coagulation status per protocol\n* Adequate hepatic function per protocol\n* Adequate renal function per protocol\n* Patient's tumor must express tumor antigen by qPCR using a fresh tumor biopsy specimen\n* Life expectancy more than 3 months\n* Confirmed availability of production capacities for IMA202 product\n* Patients must have recurrent/progressing and/or refractory solid tumors and must have received or not be eligible for all available indicated standard of care treatment.\n* For hepatocellular carcinoma (HCC) patients only, Child-Pugh score of ≤ 6\n* IMA202 product must have passed all of the release tests\n* Female patient of childbearing potential must use adequate contraception prior to study entry until 12 months after the infusion of IMA202\n* Male patient must agree to use effective contraception or be abstinent while on study and for 6 months after the infusion of IMA202\n* Hepatocellular carcinoma (HCC) patients with liver cirrhosis only - upper endoscopy is required within 6 months of study entry\n* The patient must have recovered from any side effects of prior therapy to Grade 1 or lower (except for non-clinically significant toxicities; e.g., alopecia, vitiligo) prior to lymphodepletion. As determined by the investigator, the patient may still be eligible if the patient has not fully recovered from Grade ≥ 2 toxicities if these toxicities are not anticipated to further improve (e.g., chronic neuropathy) and such toxicities are not anticipated to worsen with the lymphodepletion therapy\n\nExclusion Criteria:\n\n* History of other malignancies (except for adequately treated basal or squamous cell carcinoma or carcinoma in situ) within the last 3 years\n* Solid tumors with low likelihood of tumor biomarker expression per protocol\n* Pregnant or breastfeeding\n* Serious autoimmune disease Note: At the discretion of the investigator, these patients may be included if their disease is well controlled without the use of immunosuppressive agents.\n* History of cardiac conditions as per protocol\n* Prior stem cell transplantation or solid organ transplantation\n* Concurrent severe and/or uncontrolled medical disease that could compromise participation in the study\n* History of hypersensitivity to cyclophosphamide (CY), fludarabine (FLU), IL-2, or any of the rescue medications\n* History of or current immunodeficiency disease or prior treatment compromising immune function at the discretion of the treating physician\n* HIV infection, active hepatitis B virus (HBV), active hepatitis C virus (HCV) infection, ongoing active anti-HCV treatment or detectable HBV or HCV viral load at the most recent laboratory report. Patients with both HBV and HCV infections will be excluded from screening\n\n 1. Patients with a history of HCV infection and with an undetectable viral load per the most recent laboratory report and/or completed anti-HCV treatment but are HCV antibody positive are permitted.\n 2. History of treated HBV infection is permitted if the viral load is undetectable per the most recent laboratory report. Note: HCC patients with controlled HBV infection, as defined by resolved (anti-hepatitis B surface antigen \\[HBs-Ag\\] antibody (Ab) negative, anti-core antigen \\[HBc Ag\\] Ab positive) or chronic stable (anti HBs-Ag Ab positive) HBV infection will be eligible for screening. Patients with active HBV infection who are not on anti-HBV treatment will be excluded.\n* Any condition contraindicating leukapheresis, lymphodepletion, low-dose IL-2, and/or IMA202 treatment\n* Patients with any active viral infection\n* Patients with active brain metastases\n\nNOTE: Patients with a history of brain metastases may be eligible, if an imaging scan with contrast enhancement not older than 4 weeks is able to exclude the existence of currently active brain metastasis, and steroid therapy has been discontinued for ≥2 weeks.\n\n* Treatment with protocol-defined excluded treatments, medical devices, and/or procedures per protocol\n* Concurrent participation in an interventional part of another clinical trial."}, 'identificationModule': {'nctId': 'NCT03441100', 'acronym': 'ACTengine', 'briefTitle': 'TCR-engineered T Cells in Solid Tumors: IMA202-101', 'organization': {'class': 'INDUSTRY', 'fullName': 'Immatics US, Inc.'}, 'officialTitle': 'Phase 1 Study Evaluating Genetically Modified Autologous T Cells Expressing a T-cell Receptor Recognizing a Cancer/Germline Antigen in Patients With Recurrent and/or Refractory Solid Tumors(ACTengine® IMA202-101)', 'orgStudyIdInfo': {'id': 'IMA202-101'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Experimental: IMA202 Product', 'description': '* Pre-conditioning by non-myeloablative chemotherapy with Fludarabine and Cyclophosphamide\n* One dose of IMA202 product will be infused intravenously. Four dose levels will be evaluated. At least two patients per cohort will be treated.\n* Post-infusion of IMA202 product, administration of low dose recombinant human interleukin-2', 'interventionNames': ['Drug: IMA202 Product', 'Device: IMADetect®']}], 'interventions': [{'name': 'IMA202 Product', 'type': 'DRUG', 'description': 'The cell dose will be based on viable CD3+CD8+ HLA-Dextramer+ cells per body surface area (BSA) as defined by the Mosteller formula.', 'armGroupLabels': ['Experimental: IMA202 Product']}, {'name': 'IMADetect®', 'type': 'DEVICE', 'description': 'IMADetect® is developed as a companion diagnostic to aid in selecting patients with relapsed and/or refractory solid cancers who might be eligible for enrollment in clinical trials. IMADetect® is intended for investigational use only.', 'armGroupLabels': ['Experimental: IMA202 Product']}]}, 'contactsLocationsModule': {'locations': [{'zip': '15232', 'city': 'Pittsburgh', 'state': 'Pennsylvania', 'country': 'United States', 'facility': 'University of Pittsburgh Medical Center', 'geoPoint': {'lat': 40.44062, 'lon': -79.99589}}, {'zip': '77030', 'city': 'Houston', 'state': 'Texas', 'country': 'United States', 'facility': 'University of Texas MD Anderson Cancer Center', 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}, {'zip': '97080', 'city': 'Würzburg', 'state': 'Bavaria', 'country': 'Germany', 'facility': 'Universitätsklinikum Würzburg', 'geoPoint': {'lat': 49.79391, 'lon': 9.95121}}, {'zip': '53127', 'city': 'Bonn', 'state': 'North Rhine-Westphalia', 'country': 'Germany', 'facility': 'Universitätsklinikum Bonn - Medizinische Klinik III', 'geoPoint': {'lat': 50.73438, 'lon': 7.09549}}, {'zip': '01307', 'city': 'Dresden', 'state': 'Saxony', 'country': 'Germany', 'facility': 'Universitätsklinikum C.-G.-Carus Dresden', 'geoPoint': {'lat': 51.05089, 'lon': 13.73832}}, {'zip': '20246', 'city': 'Hamburg', 'country': 'Germany', 'facility': 'Universitätsklinikum Hamburg-Eppendorf', 'geoPoint': {'lat': 53.55073, 'lon': 9.99302}}], 'overallOfficials': [{'name': 'Cedrik Britten, MD', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Immatics US, Inc.'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Immatics US, Inc.', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}